These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 18393917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S.
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P, Kovarik J, Klauser-Braun R, Graf H, Müller HW, Veres A, Seidinger S, Ketteler M.
    Nephron Clin Pract; 2014 Aug; 126(1):39-50. PubMed ID: 24458019
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
    Donate-Correa J, Domínguez-Pimentel V, Muros-de-Fuentes M, Mora-Fernández C, Martín-Núñez E, Cazaña-Pérez V, Navarro-González JF.
    Curr Drug Targets; 2014 Aug; 15(7):703-9. PubMed ID: 24745821
    [Abstract] [Full Text] [Related]

  • 13. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž, Romozi K, Antonič M, Benedik M, Ponikvar JB, Ponikvar R, Knap B.
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [Abstract] [Full Text] [Related]

  • 19. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
    Sezer S, Tutal E, Bal Z, Uyar ME, Bal U, Cakir U, Acar NO, Haberal M.
    Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
    [Abstract] [Full Text] [Related]

  • 20. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM.
    Endocr Pract; 2008 Feb; 14(1):18-27. PubMed ID: 18238737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.